Third Harmonic Bio Inc (THRD)

NASDAQ
Currency in USD
4.85
-0.27(-5.27%)
Closed
After Hours
4.95+0.10(+2.06%)
THRD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
4.815.25
52 wk Range
4.6216.94
Key Statistics
Edit
Prev. Close
5.12
Open
5.11
Day's Range
4.81-5.25
52 wk Range
4.62-16.94
Volume
557.02K
Average Volume (3m)
242.88K
1-Year Change
-49.79%
Book Value / Share
7.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
THRD Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
17.00
Upside
+250.52%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Third Harmonic Bio Inc Company Profile

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Third Harmonic Bio Inc SWOT Analysis


Pioneering Therapy
Third Harmonic Bio's THB335, an oral wild-type KIT inhibitor, shows promise in treating mast-cell driven diseases, addressing an untapped area in inflammation and immunology
Market Potential
Analysts estimate peak US sales for chronic spontaneous urticaria at $2.7 billion, highlighting the significant commercial opportunity for THB335
Explore Clinical Progress
THB335's accelerated development timeline, with Phase 1 data expected in Q1 2025, positions Third Harmonic Bio for rapid advancement in the competitive biotech landscape
Financial Strength
With $255.3 million in cash and a current ratio of 42.5, Third Harmonic Bio is well-positioned to fund operations through 2026, supporting its ambitious clinical programs
Read full SWOT analysis

Compare THRD to Peers and Sector

Metrics to compare
THRD
Peers
Sector
Relationship
P/E Ratio
−5.6x−1.1x−0.6x
PEG Ratio
0.700.000.00
Price/Book
0.7x0.9x2.6x
Price / LTM Sales
-5.6x3.1x
Upside (Analyst Target)
291.8%287.6%47.1%
Fair Value Upside
Unlock12.4%8.1%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.00
(+250.52% Upside)

Earnings

Latest Release
Nov 07, 2024
EPS / Forecast
-0.33 / -0.2991
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

36.450
TECX
-14.44%
4.110
REVB
-3.75%
1.450
INZY
-3.33%
6.03
YMAB
-2.27%
1.990
STRO
-6.13%

FAQ

What Is the Third Harmonic Bio (THRD) Stock Price Today?

The Third Harmonic Bio stock price today is 4.85

What Stock Exchange Does Third Harmonic Bio Trade On?

Third Harmonic Bio is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Third Harmonic Bio?

The stock symbol for Third Harmonic Bio is "THRD."

What Is the Third Harmonic Bio Market Cap?

As of today, Third Harmonic Bio market cap is 218.53M.

What is Third Harmonic Bio Earnings Per Share?

The Third Harmonic Bio EPS is -0.968.

What Is the Next Third Harmonic Bio Earnings Date?

Third Harmonic Bio will release its next earnings report on 25 Mar 2025.

From a Technical Analysis Perspective, Is THRD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.